# OnCo record paper-natalee-nejm-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-natalee-nejm-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-natalee-nejm-2024" ;
  schema:name "NATALEE: three years of ribociclib after surgery in a broad population of hormone-receptor-positive early breast cancer"@en ;
  schema:description "Three years of the CDK4/6 inhibitor ribociclib added to hormone therapy reduced relapses in stage II-III hormone-receptor-positive breast cancer, including some node-negative patients."@en ;
  schema:url <https://onco.cc/key-papers/paper-natalee-nejm-2024/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2305488>, <https://clinicaltrials.gov/study/NCT03701334> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa2305488> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Slamon D, Lipatov O, Nowecki Z, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:technologies <https://onco.cc/technologies/cdk46-inhibitor/>, <https://onco.cc/technologies/endocrine-therapy/> ;
  onco:targets <https://onco.cc/targets/cdk4-6/>, <https://onco.cc/targets/estrogen-receptor/> ;
  onco:drugs <https://onco.cc/drugs/ribociclib/> ;
  onco:companies <https://onco.cc/companies/novartis/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/>, <https://onco.cc/terms/hazard-ratio/> ;
  onco:trials <https://onco.cc/trials/natalee/>, <https://onco.cc/trials/monarche/> ;
  onco:people <https://onco.cc/people/dennis-slamon/>, <https://onco.cc/people/im-seock-ah/>, <https://onco.cc/people/miguel-martin/>, <https://onco.cc/people/loi-sherene/>, <https://onco.cc/people/xu-binghe/>, <https://onco.cc/people/sara-hurvitz/>, <https://onco.cc/people/barrios-carlos/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-dormancy-mrd/>, <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-dose-optimisation/> ;
  onco:journals <https://onco.cc/journals/nejm/> .